Healthcare Triangle (HCTI): The Subscription Rebuild at Microcap Scale

Healthcare Triangle built its base business on managed cloud, data, and compliance services for hospitals, payers, and life sciences organizations, sold through three platforms with different commercial maturities. CloudEz and DataEz anchor cloud transformation, automation, data management, and governance work, and they carry HITRUST self-certification along with Business Associate Agreement coverage that lets them sit inside regulated healthcare environments. Readabl.AI extracts structured information from faxes, scanned documents, and narrative reports using public cloud machine learning, and it is the closest thing to a true subscription product in the portfolio, sold on a per-usage basis with Ezovion's hospital information system as the second subscription line. Ziloy, a mental wellness platform, rounds out the offering set. The company is a top tier healthcare and life sciences competency partner of AWS among more than 130,000 partners in that community and one of the top eight partners in Google Cloud's healthcare interoperability readiness program, which matters because certifications and hyperscaler relationships are the practical currency of trust in this niche.

The financial starting point explains why the company needed a structural event at all. Fiscal 2025 produced revenue of $13.9 million, up nearly a fifth from the year before. The year nevertheless ended with a net loss of $9.5 million. Cost of revenue of $12.0 million consumed nearly the whole top line, leaving gross margin of $1.9 million against general and administrative spending nearly four times that size. A $16.5 million operating cash outflow after working capital absorption made clear that internal funding covers neither operations nor debt service. The auditor language at the prior year end had already flagged dependence on future financings as a going concern matter.

Revenue was concentrated with the top customer at 20 percent of the total, and the top five names together carried 58 percent. A company in that position either shrinks toward profitability, sells itself, or buys growth. Management chose the third path with money it did not have in the bank, funded by the sellers themselves through deferred consideration. The cost of that choice lands on shareholders through the share count rather than through the income statement.

The strategic logic behind the Teyame purchase was to breach the microcap revenue ceiling rather than grind against it. The acquired Spanish platform, run as Teyame 360 and Datono Mediacion, pairs artificial intelligence assisted omnichannel customer experience work for financial services, insurance, and healthcare clients with an insurance intermediation business, a vertical stack that generates volume quickly and carries different margins than hospital IT services. Management framed it as a leap from healthcare IT provider to global digital innovator with forecast incremental revenue of $38 million in the next twelve months and incremental EBITDA of $5 million. The consequence for shareholders is that the investable question shifted from whether a 20 percent revenue grower can cover its overhead to whether two very different businesses, one audited and one asserted, can share a listed structure without the assertion consuming the audited base. That question is now being answered through structure, starting with the separation.

On its own evidence, the legacy franchise is a services business with thin pricing power rather than a software company with recurring economics. CloudEz and DataEz wrap cloud migration, automation, and data governance work for hospital and life sciences clients, protected less by software IP than by compliance posture: HITRUST self-certification, Business Associate Agreement support, and PCI-DSS alignment let the company operate where unqualified vendors cannot. Readabl.AI converts unstructured documents into structured clinical and administrative data on public cloud AI, and it is sold on a per-usage subscription basis, making it the clearest recurring revenue line in the portfolio alongside Ezovion, the Indian hospital information system acquired in 2025. The audited results show the scale question in one line of the income statement. Gross profit came to $1.9 million for the year on the $13.9 million revenue line. A margin structure that thin says credentialing and delivery capacity, not product lock-in, have been the real moat so far.

The Teyame assets change the product thesis in kind, not just in size. They bring an AI-enabled customer engagement stack for customer acquisition, retention, and contact center operations across financial services, insurance, and healthcare clients, plus an insurance intermediation operation, which together form a vertically integrated funnel from engagement technology to regulated distribution in Europe and Latin America. Intermediation businesses of that kind live on licensing continuity and renewal calendars, which makes revenue quality in the combined entity harder to judge from outside than either business alone. On the seller-side information the company itself disclosed, the acquired engine is pitched at odds with the legacy character.

Management's announcement cited roughly $32 million of annual revenue for fiscal 2025 from the acquired platform. The same announcement attached EBITDA of about $3.6 million to that year. If those figures hold up in audited form, the acquired business contributes better operating economics at roughly twice the size of everything the parent built over its whole listed life, which is precisely why the separation question exists.

The stated moat case for the combined entity rests on three legs, and the separation agreement is the test rig for all of them. First, compliance certification spans HITRUST and cloud partner status on the healthcare side and regulated insurance distribution experience on the Teyame side, credentials that take years to assemble and that competitors cannot shortcut. Second, a Platform Development Agreement signed with SecureKloud and Blockedge in early April commissions an integrated health advisory and care platform, including document AI tools, with intellectual property assigned exclusively to HCTI under a budget capped at about $3.2 million including contingency, effectively buying product depth at offshore development cost and clearing the old Series B entanglement with the same counterparty. Notice that the same vendor group supplies the parent's services ambitions, so delivery quality and counterparty risk now share a spine. Third, the transition services agreement makes HCTI the paid back office for Teyame, at least initially, keeping consolidated overhead visible while the two claims are priced apart. Intercompany billing as a cost-recovery vehicle is unfamiliar ground for a company of this size, and its terms decide whether shared infrastructure becomes revenue or a slow leak. Whether that stack produces durable gross margin is the open question, and the separation's separate reporting is designed to surface the answer.

The audited record through fiscal 2025 shows a business whose growth carried negative gross economics. Revenue of $13.9 million grew 19 percent from the prior year, led by software services expanding faster than the base. Yet cost of revenue rose even faster, leaving gross profit at $1.9 million. Selling expense and administrative overhead then sit on top of that thin base, and the year closed with a net loss just below the revenue line. Concentration gnaws at the edges too, because the five largest customers carried 58 percent of the year's revenue.

The first quarter of 2026 is the shape of the pivot, and it is deliberately hard to read in one number. Revenue of $9.9 million nearly tripled from the prior year quarter, and gross margin jumped to $2.4 million. Operating expense discipline did not travel with the acquired platform into the consolidated P&L. A non-cash fair value swing on acquisition liabilities inflated the net loss to $6.2 million. Receivables of $8.4 million against cash on hand of $4.3 million signal that the new revenue collects slowly and finances itself through the balance sheet rather than through shareholder returns. Intermediation-heavy businesses also recognize revenue ahead of settlement by design, so the receivable age and bad-debt behavior over the next two quarters matter as much as the headline growth itself.

Working capital discipline is the transmission mechanism between the two engines, and the filings show it under strain. Cash began the year at $7.6 million and ended March at little more than half that level after acquisition tranches. A registered direct offering priced in late February pulled in about $3.9 million of gross proceeds before a 7 percent placement fee, and a small raise after quarter end added under half a million in net terms. Equity on the balance sheet is dominated by the acquired intangible base and goodwill rather than by liquid assets. Sequencing matters more than budgeting at this scale, because each raise re-prices the next one and seller patience is itself part of the liquidity picture. None of this leaves room for error if the promised revenue recognition slips by even a quarter.

One quirk of the consolidated presentation deserves direct statement because it drives every per-share figure. A one-for-sixty reverse split is applied retroactively across all periods in the quarterly report. The weighted average share count therefore already blends the acquired platform's issuance with prior split arithmetic, while the quarter-end count of 1.8 million shares is the small residual result of those splits. Split arithmetic of that depth signals how far the old capital structure had decayed, and it buys listing compliance without buying time if the underlying economics stay unchanged. Every issuance since adds at prices well below the February offering level, and each addition further dilutes the per-share claim on the same audited history. Reported per-share figures consequently understate the dilution trajectory for anyone measuring value per current share.

Three thesis variables decide the story from here, and each has a dated checkpoint rather than a vague horizon. The first is revenue validation. The acquired platform was presented with roughly $38 million of claimed incremental revenue and about $5 million of claimed incremental EBITDA ahead of closing. A parent that earned $13.9 million in fiscal 2025 is the honest comparator. Only the next two quarterly reports can test whether those claims behave like real revenue with real receivables behind them. Agent-versus-principal classification becomes the quiet battleground, because engagement and distribution revenue stands or falls on whether the company controls what it bills for. The second is conversion gating: nearly half the stated purchase consideration sits in unissued or unconverted preferred stock that switches into common only after a shareholder vote, plus an earnout payable against performance targets. The third is separation execution: a Form 10 registration, Nasdaq listing approval for the separating entity, and a distribution date all sit between today's blended share price and any part-level valuation. Registration of that kind puts the acquired platform's statements through examination-grade scrutiny for the first time, which is the practical meaning of verification in this story.

The separation mechanics deserve a close reading because the deal terms did most of the work of making the thesis testable. Under the agreement signed in early September, HCTI distributes a minority interest in Teyame on a pro rata basis while keeping majority ownership, and the conditions include an effective Form 10, listing sign-off, and the absence of legal restraint. The same agreement transfers buyer obligations under the purchase agreement to Teyame while HCTI remains jointly liable for unpaid cash tranches and preferred consideration, which means the parent's balance sheet still backs the price even as the subsidiary reports separately. The transition services arrangement routes accounting, legal, contracting, and IT work back through HCTI with monthly billing, so overhead that looks stranded today starts its life as billable to the new entity. A taxable distribution treatment complicates the shareholder calculus in taxable accounts, and the registration and listing conditions can stretch the timeline by quarters if either stalls.

The most underread 2026 event is the SecureKloud settlement, and it carries a lesson about pre-split equity that the dilution math keeps proving. Under the original arrangement struck in late 2024, SecureKloud held preferred shares convertible into a pre-split block of 16 million common shares. That entitlement carried a market value near $7.2 million when issued. Two reverse splits with a cumulative 1:14940 ratio crushed that entitlement to barely a thousand shares, leaving the counterparty unable to realize agreed consideration for the assets it had already handed over. The June securities exchange agreement settles the matter with a fresh block of about 2.8 million split-adjusted common shares to SecureKloud or its nominee plus the Series C preferred structure created for the acquisition side, all pending a Nasdaq-required shareholder vote. The July completion of both legacy issuances, which the company then reported as lifting its exchange-traded market value near $24 million against a new listing floor measured in single-digit millions, is the practical reason that mess mattered to ordinary holders. The mechanism is a make-whole that recognizes reality: value lost through split arithmetic returns as new common count, and common holders absorb it twice, once historically and once now. None of that repair shows up as a gain anywhere in the statements, which is exactly why the mechanism belongs in the story rather than in a footnote.

Execution risk runs through a development dependency that has no substitute in-house. The Platform Development Agreement tasks SecureKloud and its subsidiary with building the integrated health advisory and care platform, document tools included, over twelve to fifteen months against a budget capped near $3.2 million including contingency, with all intellectual property assigned exclusively to HCTI. The same counterparty relationship therefore spans the product road map, a pending share issuance, and old advances of roughly $3.5 million owed over from prior years, so a deterioration in that relationship would hit product delivery exactly while the claimed growth engine still needs software depth. Management's own liquidity section expects financing activity through at least the next twelve months, which means dilution is not a scenario but an operating assumption. The honest conclusion is that the outlook carries a narrow set of dated checkpoints, and each one either validates the growth math or forces the valuation back to the audited services engine.

The reference downside is not a normal quarter, it is failure of the consideration chain. If the shareholder vote stalls or fails, the preferred consideration stays unissued and unconverted, the acquired sellers hold remedies against the parent, and the growth platform operates on a legal footing more like a concession than an owned asset. A failed registration or stalled listing approval leaves the two businesses entangled in consolidation rules with none of the part-level pricing clarity, and the jointly retained liability for the money tranches keeps the parent's cash exposed to seller demands. Receivables that collected slowly in the first quarter, over $8 million against under $5 million of cash, can turn into a working capital trough that only another raise can bridge. In that world the stock trades on survival arithmetic, the way it did before the restructuring wave, with the audited services book as the only solid floor. Markets at this scale forgive missed forecasts more slowly than they forgive missed listing compliance, and both clocks run simultaneously here.

The base case acknowledges a genuine but slower validation path. Quarterly revenue after the first half runs well above the legacy run rate but lands below the claimed next-twelve-month pace, because customer transitions, insurance distribution renewals, and a platform still being built offshore all take time. The growth engine contributes real gross profit, the consolidated cash burn narrows from the quarter-one rate but never reaches breakeven, and the financing cadence continues with the tension between dilution and runway unresolved. In that world the separation completes and the market splits the claims, and both tickets settle into microcap pricing discipline with the parent still carrying most of the goodwill and the overhead. The shareholder outcome is a re-rating of credibility rather than a re-rating of size, with value per current share drifting toward the sum of an audited services engine and a discount-to-claim stake in the acquired platform. Over that stretch, the reconciliation cadence matters more than any announcement, because demonstrated collections separate a credibility re-rating from a slow fade.

The bull case requires the acquisition math to be true in audited form and the separation to complete without mischance. On the announced information the acquired platform brought about $32 million of revenue at profitable operating economics into a much smaller structure. Management's forward claim attached $38 million of revenue and about $5 million of EBITDA to the next twelve months. Audited confirmation of either figure transforms the top line at once. A completed minority distribution gives holders a direct stake in a growth platform with separately reported margins, the transition services line converts stranded corporate cost into billable revenue, and the franchised product built under the development agreement deepens the recurring software mix at a fraction of fully loaded cost. A distribution that lands cleanly also flips the narrative burden: evidence delivered by a separately reporting subsidiary is the strongest form of proof a diluted microcap can produce. Both halves of that upside still route through one Counterparty group for platform delivery, which concentrates the bull case on a relationship rather than a market. In that world, part-level pricing reveals more value than the blended sub-dollar price ever reflected, because neither the compliance-credentialed services book nor the engagement platform had a standalone way to be valued inside one capital structure.

The counterargument deserves its own statement, because the bear case is really a fraud-and-flights-of-fancy worry wearing a valuation costume. A skeptical reader can argue that the entire sequence matters little if the seller-side financial claims are constructed: revenue assembled around short-lived telemarketing contracts, EBITDA grown on related-party economics, and intangibles recognized at negotiated values rather than cash. Every mechanized check runs through documents the sellers themselves produced, and the prior year's revenue collapse from software services shows how quickly contracts turn over at true microcap scale. The response is that structure is the only available verification: separate auditors and separate reporting under the Form 10, quarterly reconciliation of the claims against receivables and conversions, and joint liability that keeps the parent's economic incentive aligned with honest disclosure. If validation disappoints persistently, the stock re-rates to the legacy engine, and the loss is proportional rather than total, which is why position sizing belongs to the reader rather than to the thesis.

A blended sub-dollar price cannot be valued directly, so the framework below starts from audited anchors and ends at parts. The audited anchor is the services engine, and it earned revenue of $13.9 million in fiscal 2025. Gross profit for that year measured just around $1.9 million. A first quarter after consolidation then tripled the top line at a rate the legacy story alone never promised. That engine prices against peer clouds and managed services niches at a revenue multiple in the low single digits. The claimed anchor is the platform, whose seller-side presentation cited revenue near $32 million with positive operating profit for the same fiscal year. The announced next-twelve-month case attaches $38 million of revenue and about $5 million of EBITDA to the same platform. Everything between those anchors is distribution mechanics, namely unissued preferred and earnout consideration, an exchange block owed to another counterparty, and a vote that gates conversion. The honest exercise prices the audited engine conservatively and treats the claimed engine as options on verification, which is exactly what a bear, base, and bull range should express.

The bear range survives on the audited engine alone. Assign a revenue multiple of roughly one to the $13.9 million base, with no credit for unverified platform economics, and the equity arithmetic lands in a range measured in the mid-teens on paper, a qualifier doing heavy work in that sentence. In this world the unissued preferred is a contingent liability rather than an asset, and any fresh raise arrives at discount pricing. Receivables quality then becomes the swing factor, because the first quarter showed collections trailing the revenue recognition. The bear floor is real but thin, since the services book itself ran negative gross economics in its latest full year, so the floor is a liquidation-discipline number rather than a going-concern one. Certification assets and partner standing would survive any restructuring, which is precisely what keeps the floor from being zero in that scenario. Share value in that range measures in tenths of a dollar against the recent sub-dollar trading pattern.

The base case blends verified growth with partial credit for structure. Two quarters of audited consolidation near even half the claimed pace justify a combined revenue base around $30 million. A two-times revenue multiple on a microcap growth story with compliance credentials sits fairly within the range where similar names trade. Equity value near the upper tens of millions follows, and the deduction of the preferred overhang together with the exchange obligation against that figure leaves per-share value modestly above recent trading. The gap between the claimed pace and delivered results, the kind that shows up in a quarterly report, is where this case is won or lost. Pricing that gap honestly means holding both the validation cadence and the dilution ledger in view, because each new raise quietly reprices the same claim.

The bull case assumes the platform claims confirm in audited form and the separation completes on schedule. A revenue contribution at $38 million with positive margins on top of the legacy engine supports a multiple closer to three times a combined book near $50 million. Equity value in that world sits above one hundred million against a market value of listed securities reported near $24 million in late July, implying expansion through recognition rather than promotion. Separate listing of the minority stake adds part-level option value that the blended price never captured. The bull multiple is demanding, and it requires every pending mechanism, from registration effectiveness to listing approval to the conversion vote, to land in hand.

Healthcare Triangle is a bet that structure can do the work of evidence in a microcap, and so far the structure is genuinely doing work. The company converted a compliance rescue, a two-entity acquisition, and a separation blueprint into a single dated sequence, and each step has been executed so far: the claim on the growth platform exists, the exchange that cleared the old preferred entanglement is agreed with a vote pending, the market value cushion for listing compliance was rebuilt above the new threshold, and the separation agreement makes the two claims separately visible within the year. The judgment that matters is not whether the story is large, it is whether an investor can hold the share without being paid in only assertions. On the present record, roughly half that question has moved from assertion to mechanism, and mechanism with dated checkpoints is worth more than the blended price of a month ago gave it credit for. Fourth-quarter reporting and vote outcomes then settle which of the two engines earns the claim on shareholders' future cash.

The proportionality judgment matters more than the binary one. This deserves a watchlist weight at most position sizes, because the two credible failure modes both involve the same asset: the seller-side numbers turn out softer than presented, or the conversion and distribution mechanics slip while cash burn continues at the quarter-one pace. Both routes end at the audited services engine, which is a real but low-margin credentialing business with concentrated customers, and both routes arrive there through dilution that has already multiplied the share count more than tenfold inside two quarters. The upside path requires nothing to slip, four years of claimed growth to audit cleanly, and a market to price a separately listed engagement platform generously against a combined book that peers in the sector value far below such multiples today for businesses of comparable quality and comparable opacity. It deserves saying plainly that none of the tests above depends on believing management, only on reading what lands in filings.

A final judgment separates this situation from the ordinary paper-dilution pattern parts of the record resemble. Microcaps that buy growth with stock usually stack negotiated intangibles without cash anchors, related parties on multiple sides of their transactions, and disclosure that blends claims into audited figures until neither can be priced. This record shows those vices, and it also shows the antidotes arriving earlier in the sequence than the pattern usually earns. A separation agreement hands outside reviewers a separate reporting regime through which the largest claim faces audit, the services arrangement keeps the parent's own overhead visible and billed, and jointly retained liability gives the parent's board skin in honest disclosure. None of that makes the numbers true. It makes the numbers verifiable, which is a different and better place for a thesis to stand. The framework that follows is simple to state and hard to hold: hold the claim only while verification advances, weigh the audited engine alone when verification stalls, and read any acceleration in issuance beyond disclosed schedules as the costliest signal of all.